OmniAb (OABI) offers an asymmetric platform-biotech setup: a debt-free antibody discovery royalty engine with rising partner momentum, upgraded 2026 guidance, and substantial upside if late-stage partner assets convert into commercial royalties.
Overview
OmniAb Inc. is a clinical-stage biotechnology platform company that monetizes antibody discovery infrastructure through licensing, services, milestones, and downstream royalties instead of assuming the balance-sheet burden of internal drug development. **This model gives investors exposure to biologics innovation while avoiding the classic single-asset biotech binary.** The platform is built around proprietary transgenic animal systems and xPloration screening technologies that help partners generate fully human antibodies, especially against difficult or highly conserved targets where standard in vitro or rodent-only approaches can struggle. Commercial traction is substantial, with 107 partners in Q1 2026, 409 active programs, and relationships with 8 of the 10 largest global pharmaceutical companies. Financially, Q1 2026 marked a clear inflection: revenue jumped 242.9% year over year to $14.4 million, GAAP EPS of $(0.06) beat consensus $(0.10), and management raised 2026 revenue guidance to $28.0 million-$33.0 million. **The investment case hinges on scaling late-stage milestones into long-duration royalty streams** from a portfolio that includes 32 active clinical/approved programs and more than $3 billion of contracted milestone potential at an average royalty rate of 3.4%. Near-term catalysts include top-line Phase III IMVT-1402 data in H2 2026 and broader commercialization progress across partner assets.